


CLAIMS


1. A pharmaceutical composition, which comprises (a) 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)



or a pharmaceutically acceptable salt thereof and (b) a steroid agent.

2. The pharmaceutical composition according to claim 1, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and mometasone furancarboxylate.

3. An agent for treating and/or preventing a pulmonary disease, which comprises (a) 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)



(I)

or a pharmaceutically acceptable salt thereof and (b) a steroid agent as active ingredients, wherein the active ingredients are administered simultaneously or separately with an interval.

4. The agent for treating and/or preventing a pulmonary disease according to claim 3, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and mometasone furancarboxylate.


5. The agent for treating and/or preventing a pulmonary disease according to claim 3 or 4, wherein the pulmonary disease is that selected from the group consisting of chronic obstructive pulmonary diseases (COPD), pulmonary emphysema, chronic bronchitis, chronic/acute respiratory distress syndrome (ARDS), acute lung injury (ALI), asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

6. The agent for treating and/or preventing a pulmonary

disease according to claim 3 or 4, wherein the pulmonary disease is that selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

7. The agent for treating and/or preventing a pulmonary disease according to claim 3 or 4, wherein the pulmonary disease is COPD.

8. A kit which comprises (a) a first component containing 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)




(I)

or a pharmaceutically acceptable salt thereof and (b) a second component containing a steroid agent.

9. The kit according to claim 8, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and mometasone furancarboxylate.

10. A kit for treating and/or preventing a pulmonary

disease, which comprises (a) a first component containing 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)



(I)

or a pharmaceutically acceptable salt thereof and (b) a second component containing a steroid agent.

11. The kit for treating and/or preventing a pulmonary disease according to claim 10, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and mometasone furancarboxylate.


12. The kit for treating and/or preventing a pulmonary disease according to claim 10 or 11, wherein the pulmonary disease is that selected from the group consisting of COPD, pulmonary emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

13. The kit for treating and/or preventing a pulmonary disease according to claim 10 or 11, wherein the pulmonary

disease is that selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

14. The kit for treating and/or preventing a pulmonary disease according to claim 10 or 11, wherein the pulmonary disease is COPD.

15. 7-[2-(3,5-Dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)




(I)

or a pharmaceutically acceptable salt thereof, which is administered with a steroid agent simultaneously or separately with an interval.

16. 7-[2-(3,5-Dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] or a pharmaceutically acceptable salt thereof according to claim 15, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and

mometasone furancarboxylate.

17. A pharmaceutical composition, which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)




(I)

or a pharmaceutically acceptable salt thereof as an active ingredient which is administered with a steroid agent simultaneously or separately with an interval.

18. The pharmaceutical composition according to claim 17, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and mometasone furancarboxylate.

19. A method for treating and/or preventing a pulmonary disease, which comprises administering (a) 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1'-cyclopentane] represented by formula (I)



(I)

or a pharmaceutically acceptable salt thereof and (b) a steroid agent simultaneously or separately with an internal.

20. The method for treating and/or preventing a pulmonary disease according to claim 19, wherein the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, fluticasone propionate, beclomethasone propionate, budesonide, flunisolide and mometasone furancarboxylate.

21. The method for treating and/or preventing a pulmonary disease according to claim 19 or 20, wherein the pulmonary disease is that selected from the group consisting of COPD, pulmonary emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

22. The method for treating and/or preventing a pulmonary disease according to claim 19 or 20, wherein the pulmonary disease is that selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

23. The method for treating and/or preventing a pulmonary disease according to claim 19 or 20, wherein the pulmonary disease is COPD.

24. A method for treating and/or preventing a pulmonary disease, which comprises administering the pharmaceutical composition according to claim 1 or 2.

25. The method for treating and/or preventing a pulmonary disease according to claim 24, wherein the pulmonary disease is that selected from the group consisting of COPD, pulmonary emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

26. The method for treating and/or preventing a pulmonary disease according to claim 24, wherein the pulmonary disease is that selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

27. The method for treating and/or preventing a pulmonary disease according to claim 24, wherein the pulmonary disease is COPD.

28. Use of (a) and (b) according to claim 1 or 2 for manufacture of an agent for treating and/or preventing a pulmonary disease.

29. Use according to claim 28, wherein the pulmonary disease is that selected from the group consisting of COPD,



pulmonary emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

30. Use according to claim 28, wherein the pulmonary disease is that selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.

31. Use according to claim 28, wherein the pulmonary disease is COPD.